Stay updated with breaking news from Expanded Use Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...
20.02.2024 - ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients ... Seite 1
Key Developments and Financial Highlights for Investors
A team of University of Minnesota Medical School researchers successfully tested a new antifungal therapy to treat fungal meningitis. The trial results were published today in the peer-reviewed journal Clinical Infectious Diseases.